Display options
Cite
Yamaguchi F, Nasa Y, Yabe K, et al. Activation of cardiac muscarinic receptor and ischemic preconditioning effects in in situ rat heart. Heart Vessels. 1997;12(2):74-83doi: 10.1007/BF02820870.
Yamaguchi, F., Nasa, Y., Yabe, K., Ohba, S., Hashizume, Y., Ohaku, H., Furuhama, K., & Takeo, S. (1997). Activation of cardiac muscarinic receptor and ischemic preconditioning effects in in situ rat heart. Heart and vessels, 12(2), 74-83. https://doi.org/10.1007/BF02820870
Yamaguchi, F, et al. "Activation of cardiac muscarinic receptor and ischemic preconditioning effects in in situ rat heart." Heart and vessels vol. 12,2 (1997): 74-83. doi: https://doi.org/10.1007/BF02820870
Yamaguchi F, Nasa Y, Yabe K, Ohba S, Hashizume Y, Ohaku H, Furuhama K, Takeo S. Activation of cardiac muscarinic receptor and ischemic preconditioning effects in in situ rat heart. Heart Vessels. 1997;12(2):74-83. doi: 10.1007/BF02820870. PMID: 9403311.
Copy Download .nbib Format: NLM
Share it on

Heart Vessels. 1997;12(2):74-83. doi: 10.1007/BF02820870.

Activation of cardiac muscarinic receptor and ischemic preconditioning effects in in situ rat heart.

Heart and vessels

F Yamaguchi, Y Nasa, K Yabe, S Ohba, Y Hashizume, H Ohaku, K Furuhama, S Takeo

Affiliations

  1. Department of Pharmacology, Tokyo University of Pharmacy and Life Science, Japan.

PMID: 9403311 DOI: 10.1007/BF02820870

Abstract

Activation of cardiac muscarinic receptors by vagal stimulation decreases cardiac work, which may have a protective effect against ischemic injury. To determine whether cardiac muscarinic receptors contribute to the mechanisms of preconditioning effects, we examined the effect of carbachol on ischemia/reperfusion damage and the effect of vagotomy on cardioprotection induced by ischemic preconditioning. Rats were subjected to 30 min of left coronary artery occlusion followed by 30-min reperfusion in situ. Pre-conditioning was induced by three cycles of 2-min coronary artery occlusion and, subsequently by 5 min of reperfusion. The incidence of ischemic arrhythmias, such as ventricular tachycardia (VT) and ventricular fibrillation (VF), and the development of myocardial infarction were markedly reduced by the preconditioning. Carbachol infusion (4 micrograms/kg per min) delayed the occurrence of VT and VF during ischemia and reduced the infarct size. Compared with non-ischemic left ventricle, the cyclic guanosine monophosphate (GMP) content in the ischemic region of the left ventricle was decreased by ischemia/reperfusion, whereas the cyclic adenosine monophosphate (AMP) content of this region was increased. These changes were reversed by preconditioning. Similar changes in cyclic GMP and AMP content in the ischemic region were seen in rats undergoing carbachol treatment. These results suggest the possible contribution of muscarinic receptor stimulation to preconditioning. Vagotomy prior to preconditioning diminished the antiarrhythmic effects, whereas it did not block the anti-infarct effect afforded by pre-conditioning. Vagotomy abolished the preconditioning effect on the tissue cyclic GMP, but it did not attenuate the decrease in tissue cyclic AMP. The results suggest that muscarinic stimulation exerts preconditioning-mimetic protective effects in ischemic/reperfused hearts, but that a contribution of reflective vagal activity to the mechanism for preconditioning is unlikely.

References

  1. Circ Res. 1987 Sep;61(3):429-35 - PubMed
  2. Am J Physiol. 1994 May;266(5 Pt 2):H2033-41 - PubMed
  3. Am J Physiol. 1993 Jun;264(6 Pt 2):H2221-5 - PubMed
  4. Arch Biochem Biophys. 1995 Sep 10;322(1):1-13 - PubMed
  5. Cardiovasc Res. 1993 Apr;27(4):674-80 - PubMed
  6. Adv Cyclic Nucleotide Res. 1975;5:307-30 - PubMed
  7. Am J Cardiol. 1979 Jan;43(1):131-48 - PubMed
  8. Am J Pathol. 1985 Dec;121(3):522-30 - PubMed
  9. Cardiovasc Res. 1992 May;26(5):487-95 - PubMed
  10. Circulation. 1984 Jun;69(6):1182-9 - PubMed
  11. Circulation. 1973 Feb;47(2):291-8 - PubMed
  12. Am J Physiol. 1995 Jan;268(1 Pt 2):H242-9 - PubMed
  13. Am J Physiol. 1996 Dec;271(6 Pt 2):H2283-9 - PubMed
  14. Circulation. 1974 May;49(5):943-7 - PubMed
  15. J Pharmacol Exp Ther. 1994 Aug;270(2):681-9 - PubMed
  16. Circ Res. 1994 Sep;75(3):586-90 - PubMed
  17. Circ Res. 1991 Jan;68(1):61-8 - PubMed
  18. J Mol Cell Cardiol. 1993 Mar;25(3):311-20 - PubMed
  19. Br J Pharmacol. 1992 Nov;107(3):648-52 - PubMed
  20. Br J Pharmacol. 1992 Dec;107(4):910-1 - PubMed
  21. J Mol Cell Cardiol. 1995 Apr;27(4):991-1000 - PubMed
  22. Circ Res. 1989 Mar;64(3):437-48 - PubMed
  23. FASEB J. 1990 Apr 1;4(6):1668-73 - PubMed
  24. Br J Pharmacol. 1995 Aug;115(8):1532-8 - PubMed
  25. Am J Physiol. 1987 Dec;253(6 Pt 2):H1470-6 - PubMed
  26. Circ Res. 1993 Dec;73(6):1193-201 - PubMed
  27. Cardiovasc Res. 1988 Jul;22(7):447-55 - PubMed
  28. Am J Physiol. 1996 Jul;271(1 Pt 2):H23-8 - PubMed
  29. Circ Res. 1996 Jan;78(1):137-47 - PubMed
  30. Cardiovasc Res. 1992 Oct;26(10):983-7 - PubMed
  31. Proc Natl Acad Sci U S A. 1993 Jan 1;90(1):347-51 - PubMed
  32. Circulation. 1995 Sep 15;92(6):1558-64 - PubMed
  33. Am Heart J. 1992 Feb;123(2):346-53 - PubMed
  34. Trends Pharmacol Sci. 1994 Jan;15(1):19-25 - PubMed
  35. Circulation. 1986 Nov;74(5):1124-36 - PubMed
  36. Adv Cardiol. 1978;25:119-29 - PubMed
  37. Am J Physiol. 1993 Jul;265(1 Pt 2):H176-82 - PubMed
  38. Am J Physiol. 1986 Dec;251(6 Pt 2):H1306-15 - PubMed
  39. Circ Res. 1990 Apr;66(4):1133-42 - PubMed
  40. Br J Pharmacol. 1994 Dec;113(4):1167-72 - PubMed

Substances

MeSH terms

Publication Types